Aquinox Pharmaceuticals Incorporated (NASDAQ:AQXP)’s Stock Is Buy After Less Market Selling

October 13, 2017 - By Adrian Mccoy

 Aquinox Pharmaceuticals Incorporated (NASDAQ:AQXP)'s Stock Is Buy After Less Market Selling

The stock of Aquinox Pharmaceuticals Incorporated (NASDAQ:AQXP) registered a decrease of 3.16% in short interest. AQXP’s total short interest was 1.05M shares in October as published by FINRA. Its down 3.16% from 1.08M shares, reported previously. With 66,800 shares average volume, it will take short sellers 16 days to cover their AQXP’s short positions. The short interest to Aquinox Pharmaceuticals Incorporated’s float is 11.07%.

The stock decreased 0.14% or $0.02 on October 13, reaching $13.98. About 30,464 shares traded. Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) has risen 122.35% since October 13, 2016 and is uptrending. It has outperformed by 105.65% the S&P500.

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The company has market cap of $328.04 million. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 -containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. It currently has negative earnings. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing.

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Ratings Coverage

Among 6 analysts covering Aquinox Pharma (NASDAQ:AQXP), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Aquinox Pharma had 10 analyst reports since September 11, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Leerink Swann given on Monday, September 21. The stock has “Buy” rating by Needham on Friday, October 23. The firm has “Buy” rating given on Tuesday, October 6 by Guggenheim. The firm has “Hold” rating by Jefferies given on Friday, August 5. Canaccord Genuity maintained Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) rating on Friday, September 11. Canaccord Genuity has “Hold” rating and $22 target. As per Tuesday, March 15, the company rating was maintained by Jefferies. The rating was maintained by Needham on Tuesday, August 8 with “Buy”. The firm has “Buy” rating given on Tuesday, August 8 by Canaccord Genuity.

More recent Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) news were published by: Seekingalpha.com which released: “Aquinox Pharmaceuticals: Patience Will Be Rewarded” on April 04, 2017. Also Fool.com published the news titled: “Can Shares of Aquinox Pharmaceuticals Continue to Rocket Higher?” on February 28, 2017. Seekingalpha.com‘s news article titled: “Aquinox Pharmaceuticals: Buy, Sell Or Hold?” with publication date: September 01, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.